公司战略选择 - CENTOGENE宣布决定探索一系列旨在为利益相关者创造可持续长期价值的战略选择[1] 产品创新 - 公司在2023年取得了重大进展，推出了创新和高影响力的基因组和多组学产品[2] 管理层合作评估 - 管理层正在与监事会合作评估可用选项，以确保CENTOGENE处于增长和盈利路径上最佳位置[3]

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and the Laboratory of Human Genetics of Infectious Diseases (the "Lab") at Institut Imagine today announced a strategic research collaboration to improve health outcomes for rare disease patients by accelerating and de-risking drug discovery and clinical development. As part of the ...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France. Accordingly, it has received accreditation under the French R&D tax credit initiative ('Crédit d'Impôt Recherche', ...

合作研究项目 - Centogene N.V.与The Michael J. Fox Foundation for Parkinson's Research宣布合作进行研究项目，加速研究与帕金森病相关的GBA基因的遗传风险因素[1] - 该研究项目将利用CENTOGENE在罕见遗传和神经退行性疾病方面的专业知识，利用CENTOGENE生物数据库中的多样性多组学数据，旨在建立对特定GBA基因变异与帕金森病之间关系的更深入理解[2] - 通过与The Michael J. Fox Foundation的合作，CENTOGENE旨在加速研究特定风险因素，以帮助更好地诊断、理解和治疗这种影响全球数百万患者的疾病[4]

Exhibit 99.1 CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Prof. Dr. Peter Bauer as a m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal y ear ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...